These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 30487133)

  • 41. Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study.
    Troeltzsch M; Woodlock T; Pianka A; Otto S; Troeltzsch M; Ehrenfeld M; Knösel T
    J Oral Maxillofac Surg; 2017 May; 75(5):969-977. PubMed ID: 27916470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
    Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
    Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
    Amoils M; Kim J; Lee C; Sunwoo JB; Colevas AD; Aasi SZ; Hollmig ST; Ma Y; Divi V
    Otolaryngol Head Neck Surg; 2019 Jan; 160(1):93-99. PubMed ID: 30012051
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Immune Checkpoint BTLA in Oral Cancer: Expression Analysis and Its Correlation to Other Immune Modulators.
    Ries J; Trumet L; Hahn A; Kunater L; Lutz R; Geppert C; Kesting M; Weber M
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928307
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma.
    Kim SA; Lee KH; Lee DH; Lee JK; Lim SC; Joo YE; Chung IJ; Noh MG; Yoon TM
    Int J Oncol; 2019 Aug; 55(2):513-526. PubMed ID: 31268163
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
    Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases.
    García-Díez I; Hernández-Ruiz E; Andrades E; Gimeno J; Ferrándiz-Pulido C; Yébenes M; García-Patos V; Pujol RM; Hernández-Muñoz I; Toll A
    Am J Dermatopathol; 2018 Sep; 40(9):647-654. PubMed ID: 29742559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Study of the PD-L1 expression, T-cells density and immunoscore in paired baseline tumor biopsies and surgical specimens in squamous cell carcinoma of the oral cavity.
    Beyaert S; Borys A; Baldin P; Dahou H; Magremanne M; Mahy P; Renwart W; Machiels JP; Schmitz S
    Oral Oncol; 2024 Jul; 154():106869. PubMed ID: 38820890
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
    Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
    Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K
    Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
    Furukawa K; Kawasaki G; Yoshida T; Umeda M
    Anticancer Res; 2021 Jan; 41(1):101-111. PubMed ID: 33419803
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study.
    Dave K; Ali A; Magalhaes M
    Sci Rep; 2020 Jun; 10(1):9705. PubMed ID: 32546692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD163
    Kubota K; Moriyama M; Furukawa S; Rafiul HASM; Maruse Y; Jinno T; Tanaka A; Ohta M; Ishiguro N; Yamauchi M; Sakamoto M; Maehara T; Hayashida JN; Kawano S; Kiyoshima T; Nakamura S
    Sci Rep; 2017 May; 7(1):1755. PubMed ID: 28496107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs.
    Ahmadvand S; Norouzi LA; Mohammadi Y; Safaei A; Khademi B; Motiee-Langroudi M; Ghaderi A
    BMC Immunol; 2024 Jan; 25(1):7. PubMed ID: 38229027
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma.
    Kim HS; Lee JY; Lim SH; Park K; Sun JM; Ko YH; Baek CH; Son YI; Jeong HS; Ahn YC; Lee MY; Hong M; Ahn MJ
    Cancer Res Treat; 2016 Apr; 48(2):527-36. PubMed ID: 26511814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.
    Oliveira-Costa JP; de Carvalho AF; da Silveira da GG; Amaya P; Wu Y; Park KJ; Gigliola MP; Lustberg M; Buim ME; Ferreira EN; Kowalski LP; Chalmers JJ; Soares FA; Carraro DM; Ribeiro-Silva A
    Oncotarget; 2015 Aug; 6(25):20902-20. PubMed ID: 26041877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.